Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113


The octadecyloxyethyl ester of (S)-9-[3-hydroxy-2-(phosphonomethoxy) propyl]adenine is a potent and selective inhibitor of hepatitis C virus replication in genotype 1A, 1B, and 2A replicons.

Wyles DL, Kaihara KA, Korba BE, Schooley RT, Beadle JR, Hostetler KY.

Antimicrob Agents Chemother. 2009 Jun;53(6):2660-2. doi: 10.1128/AAC.01546-08. Epub 2009 Mar 16.


Synthesis and antiviral evaluation of 9-(S)-[3-alkoxy-2-(phosphonomethoxy)propyl]nucleoside alkoxyalkyl esters: inhibitors of hepatitis C virus and HIV-1 replication.

Valiaeva N, Wyles DL, Schooley RT, Hwu JB, Beadle JR, Prichard MN, Hostetler KY.

Bioorg Med Chem. 2011 Aug 1;19(15):4616-25. doi: 10.1016/j.bmc.2011.06.009. Epub 2011 Jun 13.


Alkoxyalkyl esters of 9-(s)-(3-hydroxy-2-phosphonomethoxypropyl) adenine are potent and selective inhibitors of hepatitis B virus (HBV) replication in vitro and in HBV transgenic mice in vivo.

Morrey JD, Korba BE, Beadle JR, Wyles DL, Hostetler KY.

Antimicrob Agents Chemother. 2009 Jul;53(7):2865-70. doi: 10.1128/AAC.00114-09. Epub 2009 Apr 27.


Antiviral evaluation of octadecyloxyethyl esters of (S)-3-hydroxy-2-(phosphonomethoxy)propyl nucleosides against herpesviruses and orthopoxviruses.

Valiaeva N, Prichard MN, Buller RM, Beadle JR, Hartline CB, Keith KA, Schriewer J, Trahan J, Hostetler KY.

Antiviral Res. 2009 Dec;84(3):254-9. doi: 10.1016/j.antiviral.2009.09.012. Epub 2009 Oct 1.


Effect of oral treatment with hexadecyloxypropyl-[(S)-9-(3-hydroxy-2- phosphonylmethoxypropyl)adenine] [(S)-HPMPA] or octadecyloxyethyl-(S)-HPMPA on cowpox or vaccinia virus infections in mice.

Quenelle DC, Collins DJ, Herrod BP, Keith KA, Trahan J, Beadle JR, Hostetler KY, Kern ER.

Antimicrob Agents Chemother. 2007 Nov;51(11):3940-7. Epub 2007 Sep 10.


Inhibition of HIV-1 by octadecyloxyethyl esters of (S)-[3-hydroxy-2-(phosphonomethoxy)propyl] nucleosides and evaluation of their mechanism of action.

Magee WC, Valiaeva N, Beadle JR, Richman DD, Hostetler KY, Evans DH.

Antimicrob Agents Chemother. 2011 Nov;55(11):5063-72. doi: 10.1128/AAC.05161-11. Epub 2011 Sep 6.


Effect of oral treatment with (S)-HPMPA, HDP-(S)-HPMPA or ODE-(S)-HPMPA on replication of murine cytomegalovirus (MCMV) or human cytomegalovirus (HCMV) in animal models.

Quenelle DC, Collins DJ, Pettway LR, Hartline CB, Beadle JR, Wan WB, Hostetler KY, Kern ER.

Antiviral Res. 2008 Aug;79(2):133-5. doi: 10.1016/j.antiviral.2008.01.155. Epub 2008 Feb 22.


PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication.

Lam AM, Murakami E, Espiritu C, Steuer HM, Niu C, Keilman M, Bao H, Zennou V, Bourne N, Julander JG, Morrey JD, Smee DF, Frick DN, Heck JA, Wang P, Nagarathnam D, Ross BS, Sofia MJ, Otto MJ, Furman PA.

Antimicrob Agents Chemother. 2010 Aug;54(8):3187-96. doi: 10.1128/AAC.00399-10. Epub 2010 Jun 1.


Antischistosomal activity of hexadecyloxypropyl cyclic 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine and other alkoxyalkyl esters of acyclic nucleoside phosphonates assessed by schistosome worm killing in vitro.

Botros SS, William S, Beadle JR, Valiaeva N, Hostetler KY.

Antimicrob Agents Chemother. 2009 Dec;53(12):5284-7. doi: 10.1128/AAC.00840-09. Epub 2009 Aug 24.


Synthesis and antiviral evaluation of alkoxyalkyl derivatives of 9-(S)-(3-hydroxy-2-phosphonomethoxypropyl)adenine against cytomegalovirus and orthopoxviruses.

Beadle JR, Wan WB, Ciesla SL, Keith KA, Hartline C, Kern ER, Hostetler KY.

J Med Chem. 2006 Mar 23;49(6):2010-5.


Novel hepatitis C virus reporter replicon cell lines enable efficient antiviral screening against genotype 1a.

Robinson M, Yang H, Sun SC, Peng B, Tian Y, Pagratis N, Greenstein AE, Delaney WE 4th.

Antimicrob Agents Chemother. 2010 Aug;54(8):3099-106. doi: 10.1128/AAC.00289-10. Epub 2010 Jun 1.


Replication studies using genotype 1a subgenomic hepatitis C virus replicons.

Gu B, Gates AT, Isken O, Behrens SE, Sarisky RT.

J Virol. 2003 May;77(9):5352-9.


Synthesis, metabolic stability and antiviral evaluation of various alkoxyalkyl esters of cidofovir and 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine.

Ruiz J, Beadle JR, Buller RM, Schreiwer J, Prichard MN, Keith KA, Lewis KC, Hostetler KY.

Bioorg Med Chem. 2011 May 1;19(9):2950-8. doi: 10.1016/j.bmc.2011.03.034. Epub 2011 Mar 23.


In vitro efficacy of approved and experimental antivirals against novel genotype 3 hepatitis C virus subgenomic replicons.

Yu M, Corsa AC, Xu S, Peng B, Gong R, Lee YJ, Chan K, Mo H, Delaney W 4th, Cheng G.

Antiviral Res. 2013 Nov;100(2):439-45. doi: 10.1016/j.antiviral.2013.08.018. Epub 2013 Sep 5.


Comparison of HCV NS3 protease and NS5B polymerase inhibitor activity in 1a, 1b and 2a replicons and 2a infectious virus.

Paulson MS, Yang H, Shih IH, Feng JY, Mabery EM, Robinson MF, Zhong W, Delaney WE 4th.

Antiviral Res. 2009 Aug;83(2):135-42. doi: 10.1016/j.antiviral.2009.04.003. Epub 2009 Apr 14.


HCV NS5A replication complex inhibitors. Part 4. Optimization for genotype 1a replicon inhibitory activity.

St Laurent DR, Serrano-Wu MH, Belema M, Ding M, Fang H, Gao M, Goodrich JT, Krause RG, Lemm JA, Liu M, Lopez OD, Nguyen VN, Nower PT, O'Boyle DR 2nd, Pearce BC, Romine JL, Valera L, Sun JH, Wang YK, Yang F, Yang X, Meanwell NA, Snyder LB.

J Med Chem. 2014 Mar 13;57(5):1976-94. doi: 10.1021/jm301796k. Epub 2013 Apr 10.


Evaluation of nucleoside phosphonates and their analogs and prodrugs for inhibition of orthopoxvirus replication.

Keith KA, Hitchcock MJ, Lee WA, HolĂ˝ A, Kern ER.

Antimicrob Agents Chemother. 2003 Jul;47(7):2193-8.


Preclinical characterization of GSK2336805, a novel inhibitor of hepatitis C virus replication that selects for resistance in NS5A.

Walker J, Crosby R, Wang A, Woldu E, Vamathevan J, Voitenleitner C, You S, Remlinger K, Duan M, Kazmierski W, Hamatake R.

Antimicrob Agents Chemother. 2014;58(1):38-47. doi: 10.1128/AAC.01363-13. Epub 2013 Oct 14.

Items per page

Supplemental Content

Write to the Help Desk